The Diabetic Therapeutic Market report is equipped with market data from 2013 to 2023. The report gives a market overview covering key drivers and risks factors. The report is bifurcated by top global manufactures mentioning sales, revenue and prices as applicable. It also evaluates the competitive scenario of the leading players. The report expands to cover regional market data along with type and application. The report forecasts sales and revenue from 2018 to 2023. The detailed sales channel is also covered in the study.
The global diabetic therapeutic market is growing at a high pace owing to the increase in the prevalence of diabetes globally. The top countries with high prevalence of diabetes are China, India, the US, Brazil, Russia, Mexico, Indonesia, Egypt, Japan, and Bangladesh. It is estimated that more than 1.5 million deaths occur due to diabetes worldwide each year.
Scope of the Report:
This report studies the Diabetic Therapeutic market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Diabetic Therapeutic market by product type and applications/end industries.
The report identifies the increasing focus on the self-management of diabetes to be one of the major factors that will have a positive impact on the growth of this market in the coming years. With the recent years witnessing an increase in number of people diagnosed with type 1 diabetes, there has been considerable increase in the adoption of insulin delivery systems. Focusing on skipping the need to schedule appointments and reduce expenses for clinical visits, increases the adoption of insulin delivery systems, where individuals use insulin injections at home under the guidance of a physician. This led to the introduction of insulin pens, pumps, and jet injectors, which, in turn, will drive the growth of the diabetic therapeutics market.
Characterized by the presence of numerous small and large-scale vendors, the diabetes treatment market appears to be highly competitive. The market is dominated by the major players such as AstraZeneca, Novo Nordisk, Merck, Eli Lilly, and Sanofi who are competing against each other to lead the market. The market also consists of a number of local manufacturers in various countries and will also witness the entry of several new players, which will further intensify the level of competition in the market. To increase their revenue shares and improve market position, vendors are focusing on strategic alliances which will help them in marketing and manufacturing drugs.
In terms of geographical regions, the Americas will be the major revenue contributor to the diabetic therapeutics market throughout the predicted period. The increasing prevalence of diabetes in countries such as the US, which provides opportunities for vendors to develop new, more efficient, and safer drugs will be the major factor driving market growth in this segment.
The global Diabetic Therapeutic market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Diabetic Therapeutic.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
- AstraZeneca
- Eli Lilly
- Merck
- Novo Nordisk
- Sanofi
- AbbVie
- Actelion Pharmaceuticals
- Adocia
- Aegerion Pharmaceuticals
- Akros Pharma
- Alnylam Pharmaceuticals
- Amarin
- Amgen
- Amicus Therapeutics
- Arbutus Biopharma
- Arena Pharmaceuticals
- Astellas Pharma
- Atheronova
- Biodel
- BioMarin
- Bionaturis
- Biosidus
- Biospherics
- Boehringer Ingelheim
- Bristol-Myers Squibb
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Type 1
- Type 2
- Gestational
Market Segment by Applications, can be divided into
- Insulin therapies
- Non-insulin therapies